AI Article Synopsis
- Age-related macular degeneration (ARMD) is a complex disease that leads to significant vision loss and has unknown causes.
- The current treatment focuses on managing symptoms, specifically targeting choroidal neovascularization (CNV) through various therapeutic options that are hard to categorize.
- Photodynamic therapy (PDT) using verteporfirin is the standard method for treating CNV, alongside discussing new therapies and alternative approaches like transpupillary thermotherapy and anti-angiogenic treatments.
Article Abstract
Age-related macular degeneration (ARMD) is a multifactorial disease, with unknown etiology, which represents one of the main causes of legal blindness. At this moment, the only treatment for ARMD is symptomatic and concerns the distinction of the choroidal neovascularisation (CNV). There are many therapeutical procedures, and their classification is difficult. The dynamic phototherapy (PDT) with intravenous injection of verteporfirin (Visudyne), a recent therapeutic concept based on a photochemical reaction, represents the only standard procedure for destroying the macular CNVs. The paper presents new therapeutical procedures, discussing them in relation with PDT. Beside the PDT and its supporting methods, other competing techniques (transpupillary thermotherapy, surgical removal, anti-angiogenesis and antioxidants) are presented.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!